(Total Views: 540)
Posted On: 03/05/2021 9:39:15 PM
Post# of 155778
“What I am saying is that we have only recieved part of the data.”
Investors shouldn’t hold their breath for the severe data. Severe patients are less sick then critical, so the data points from the trial protocol were likely not met. Could there be other endpoints that CYDY can mine? Possibly, but we’ll have to wait and see. Good news is that there were over 300 severe patients in the trial so we’ve got plenty of data (the guy who NP sent out to enroll patients should be fired).
“With that said, our data set is small and it appears the US FDA is going to want to see more data.”
Yes, more time and money. 62 patients is basically a small phase 2 trial, like the LH trial that the FDA just approved. Let’s hope the FDA doesn’t ask for a high number, but we weren’t provided the p value of mortality or the overall power. CYDY also needs to ensure that only critical patients are enrolled form here forward.
Investors shouldn’t hold their breath for the severe data. Severe patients are less sick then critical, so the data points from the trial protocol were likely not met. Could there be other endpoints that CYDY can mine? Possibly, but we’ll have to wait and see. Good news is that there were over 300 severe patients in the trial so we’ve got plenty of data (the guy who NP sent out to enroll patients should be fired).
“With that said, our data set is small and it appears the US FDA is going to want to see more data.”
Yes, more time and money. 62 patients is basically a small phase 2 trial, like the LH trial that the FDA just approved. Let’s hope the FDA doesn’t ask for a high number, but we weren’t provided the p value of mortality or the overall power. CYDY also needs to ensure that only critical patients are enrolled form here forward.
(5)
(0)
